NLY01 for Multiple Sclerosis

(TAG-MS Trial)

This trial tests a new treatment, NLY01 (an experimental drug), for people with Multiple Sclerosis (MS). The goal is to determine if this treatment can reduce brain and retinal shrinkage by lowering inflammation, potentially slowing the damage MS causes to the nervous system. Participants will receive either the study drug or a placebo (inactive treatment) to compare effects. Those who have been clinically stable on MS therapy for at least a year and have a body mass index of 27 or more may be suitable candidates. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you need to stop your current medications, but it does exclude certain medications like insulin, insulin-inducing medications, and specific diabetes drugs. It's best to discuss your current medications with the study team to see if they are allowed.

Research has shown that NLY01 has been tested in people and found to be safe and well-tolerated. In a study on Parkinson's disease, NLY01 showed no major side effects. Additionally, early results in people with multiple sclerosis suggest that treatments like NLY01 are generally well-tolerated and may offer benefits. These findings indicate that NLY01 could be a safe option for further testing in multiple sclerosis.¹²³⁴⁵

NLY01 is unique because it targets the immune system in a different way than standard multiple sclerosis (MS) treatments, like interferons or monoclonal antibodies. NLY01 acts by inhibiting a protein called glucagon-like peptide-1 (GLP-1), which may offer neuroprotective effects and potentially slow down the progression of MS. This approach could provide a novel strategy for managing MS, offering hope for better outcomes in terms of slowing disease progression and reducing symptoms. Researchers are excited about this treatment because it represents a fresh approach to tackling the challenges of MS.

Research has shown that NLY01, a new treatment tested in this trial, might help people with Multiple Sclerosis (MS) by reducing inflammation and slowing nerve damage. Earlier studies indicate that NLY01 can protect the nerve coating, often damaged in MS, by preventing certain immune cells from attacking the nerves. Animal studies also suggest that NLY01 can protect the brain and spinal cord, potentially leading to fewer symptoms for people with MS. Overall, these findings suggest that NLY01 could be a promising option for slowing MS progression. Participants in this trial will receive either NLY01 or a placebo to evaluate its effectiveness.¹²⁵⁶⁷